| Autor: |
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, Ganiraju Manyam, Bryan K Kee, David R Fogelman, Arvind Dasari, Kanwal Raghav, Eduardo Vilar, Shanequa Manuel, Imad Shureiqi, Robert A Wolff, Keyur P Patel, Raja Luthra, Kenna Shaw, Cathy Eng, Dipen M Maru, Mark J Routbort, Funda Meric-Bernstam, Scott Kopetz |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 12, Iss 3, p e0173345 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0173345 |
| Popis: |
SMAD4 is an essential mediator in the transforming growth factor-β pathway. Sporadic mutations of SMAD4 are present in 2.1-20.0% of colorectal cancers (CRCs) but data are limited. In this study, we aimed to evaluate clinicopathologic characteristics, prognosis, and clinical outcome associated with this mutation in CRC cases. Data for patients with metastatic or unresectable CRC who underwent genotyping for SMAD4 mutation and received treatment at The University of Texas MD Anderson Cancer Center from 2000 to 2014 were reviewed. Their tumors were sequenced using a hotspot panel predicted to cover 80% of the reported SMAD4 mutations, and further targeted resequencing that included full-length SMAD4 was performed on mutated tumors using a HiSeq sequencing system. Using The Cancer Genome Atlas data on CRC, the characteristics of SMAD4 and transforming growth factor-β pathway mutations were evaluated according to different consensus molecular subtypes of CRC. Among 734 patients with CRC, 90 (12%) had SMAD4 mutations according to hotspot testing. SMAD4 mutation was associated with colon cancer more so than with rectal cancer (odds ratio 2.85; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
